share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股变动声明
SEC announcement ·  03/22 17:48
Moomoo AI 已提取核心信息
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
据报道，CRISPR Therapeutics总法律顾问兼秘书詹姆斯·卡辛格参与了一项涉及该公司股票的交易。该行动于 2024 年 3 月 20 日进行。但是，该公告没有透露行动类型、状态、所涉股票数量、股票性质、交易价格或交易后的持股细节。如果没有这些细节，投资者尚不清楚这一事件对CRISPR Therapeutics股票的影响。
据报道，CRISPR Therapeutics总法律顾问兼秘书詹姆斯·卡辛格参与了一项涉及该公司股票的交易。该行动于 2024 年 3 月 20 日进行。但是，该公告没有透露行动类型、状态、所涉股票数量、股票性质、交易价格或交易后的持股细节。如果没有这些细节，投资者尚不清楚这一事件对CRISPR Therapeutics股票的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息